R & D
Our Commitment to R&D and Innovation
Bracco Imaging devotes considerable effort and substantial resources to research and development (R&D), in order to create and develop innovative products addressing unmet or poorly met medical needs. Another R&D goal is the conception and implementation of high-efficiency production processes with special attention to minimize their environmental impact.
Bracco Imaging carries out its R&D activities in the Research Centers of Colleretto Giacosa (Ivrea, Italy) and Plan-les-Ouates (Geneva, Switzerland).
Our Group currently owns approximately 1,500 patents registered throughout the world. Our history of developing proprietary products includes: iopamidol, the first ready-to-use, non-ionic / low osmolar contrast agent for X-Ray, launched in 1981 and still the leading product in many markets under different brand names; MultiHance®, the magnetic resonance imaging (MRI) contrast agent with high relaxivity and dual route of excretion, launched in 1998; and obtained approval for expanded labeling in magnetic resonance angiography (MRA) in 2012; and CardioGen-82® the first and only agent approved for cardiac positron emission tomography (PET) myocardial perfusion imaging.
The Group is currently engaged in the development of new imaging agents and solutions, specifically designed to improve patient management through increased accuracy in diagnoses.
To read more about our commitment to R&D and innovation, click here.